Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H28N4O11 |
Molecular Weight | 608.5528 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(CO)NN1C(=O)C2=C(C1=O)C3=C(N([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C5=C3C=CC(O)=C5)C6=C2C7=C(N6)C=C(O)C=C7
InChI
InChIKey=QMVPQBFHUJZJCS-NTKFZFFISA-N
InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1
Edotecarin (J-107088 or [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carb azo le-5,7(6H)-dione]) is a DNA topoisomerase I inhibitor. The antitumor activity of edotecarin has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in breast, cervix, pharynx, lung, prostate, colon, gastric, and hepatic cancer models. Banyu Pharmaceutical Co Ltd and Pfizer Inc were developing edotecarin for the potential treatment of solid tumors. Edotecarin development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16819636
The recommended Phase II dose of edotecarin is 13 mg/m(2) once every 21 days.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1904
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1V8X590XDP
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL435191
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
C2665
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
8246
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
100000089430
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
m4830
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB04882
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
DTXSID40870123
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
C121395
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
174402-32-5
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
9808998
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
RR-32
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY | |||
|
SUB25404
Created by
admin on Sat Dec 16 15:57:28 GMT 2023 , Edited by admin on Sat Dec 16 15:57:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY